메뉴 건너뛰기




Volumn 91, Issue 5, 2016, Pages 492-498

Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; AZACITIDINE; CD135 ANTIGEN; DECITABINE; DNA METHYLTRANSFERASE 3A; HYDROXYUREA; IMETELSTAT; JANUS KINASE 2; LENALIDOMIDE; SMALL NUCLEAR RNA; ASXL1 PROTEIN, HUMAN; CARRIER PROTEIN; HEMOGLOBIN; JAK2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; REPRESSOR PROTEIN; SETBP1 PROTEIN, HUMAN; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN; STOP CODON;

EID: 84962724166     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24332     Document Type: Article
Times cited : (76)

References (25)
  • 2
    • 84929458274 scopus 로고    scopus 로고
    • Refractory anemia with ring sideroblasts and RARS with thrombocytosis
    • Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts and RARS with thrombocytosis. Am J Hematol 2015; 90:549-559.
    • (2015) Am J Hematol , vol.90 , pp. 549-559
    • Patnaik, M.M.1    Tefferi, A.2
  • 3
    • 84926359679 scopus 로고    scopus 로고
    • Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations
    • Jeromin S, Haferlach T, Weissmann S, et al. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations. Haematologica 2015; 100:e125-e127.
    • (2015) Haematologica , vol.100 , pp. e125-e127
    • Jeromin, S.1    Haferlach, T.2    Weissmann, S.3
  • 4
    • 84863971025 scopus 로고    scopus 로고
    • Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis
    • Broseus J, Florensa L, Zipperer E, et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica 2012; 97:1036-1041.
    • (2012) Haematologica , vol.97 , pp. 1036-1041
    • Broseus, J.1    Florensa, L.2    Zipperer, E.3
  • 5
    • 84855841586 scopus 로고    scopus 로고
    • SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value
    • Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012; 119:569-572.
    • (2012) Blood , vol.119 , pp. 569-572
    • Patnaik, M.M.1    Lasho, T.L.2    Hodnefield, J.M.3
  • 6
    • 84902107409 scopus 로고    scopus 로고
    • Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis
    • Broseus J, Lippert E, Harutyunyan AS, et al. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2014; 28:1374-1376.
    • (2014) Leukemia , vol.28 , pp. 1374-1376
    • Broseus, J.1    Lippert, E.2    Harutyunyan, A.S.3
  • 7
    • 84890372480 scopus 로고    scopus 로고
    • Somatic mutations of calreticulin in myeloproliferative neoplasms
    • Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369:2379-2390.
    • (2013) N Engl J Med , vol.369 , pp. 2379-2390
    • Klampfl, T.1    Gisslinger, H.2    Harutyunyan, A.S.3
  • 8
    • 84890328032 scopus 로고    scopus 로고
    • Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2
    • Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369:2391-2405.
    • (2013) N Engl J Med , vol.369 , pp. 2391-2405
    • Nangalia, J.1    Massie, C.E.2    Baxter, E.J.3
  • 9
    • 84883741044 scopus 로고    scopus 로고
    • Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis
    • Broseus J, Alpermann T, Wulfert M, et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2013; 27:1826-1831.
    • (2013) Leukemia , vol.27 , pp. 1826-1831
    • Broseus, J.1    Alpermann, T.2    Wulfert, M.3
  • 10
    • 84880263477 scopus 로고    scopus 로고
    • Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
    • Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013; 27:1504-1510.
    • (2013) Leukemia , vol.27 , pp. 1504-1510
    • Patnaik, M.M.1    Padron, E.2    LaBorde, R.R.3
  • 11
    • 84922332658 scopus 로고    scopus 로고
    • ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two-center study of 466 patients
    • Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two-center study of 466 patients. Leukemia 2014; 28:2206-2212.
    • (2014) Leukemia , vol.28 , pp. 2206-2212
    • Patnaik, M.M.1    Itzykson, R.2    Lasho, T.L.3
  • 12
    • 84940845882 scopus 로고    scopus 로고
    • A pilot study of the telomerase inhibitor imetelstat for myelofibrosis
    • Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 2015; 373:908-919.
    • (2015) N Engl J Med , vol.373 , pp. 908-919
    • Tefferi, A.1    Lasho, T.L.2    Begna, K.H.3
  • 13
    • 84874303759 scopus 로고    scopus 로고
    • Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance
    • Patnaik MM, Lasho TL, Finke CM, et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance. Am J Hematol 2013; 88:201-206.
    • (2013) Am J Hematol , vol.88 , pp. 201-206
    • Patnaik, M.M.1    Lasho, T.L.2    Finke, C.M.3
  • 14
    • 84862497037 scopus 로고    scopus 로고
    • Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts
    • Patnaik MM, Hanson CA, Sulai NH, et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. Blood 2012; 119:5674-5677.
    • (2012) Blood , vol.119 , pp. 5674-5677
    • Patnaik, M.M.1    Hanson, C.A.2    Sulai, N.H.3
  • 15
    • 84883743018 scopus 로고    scopus 로고
    • CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia
    • Pardanani A, Lasho TL, Laborde RR, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013; 27:1870-1873.
    • (2013) Leukemia , vol.27 , pp. 1870-1873
    • Pardanani, A.1    Lasho, T.L.2    Laborde, R.R.3
  • 16
    • 84877608004 scopus 로고    scopus 로고
    • Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
    • Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013; 368:1781-1790.
    • (2013) N Engl J Med , vol.368 , pp. 1781-1790
    • Maxson, J.E.1    Gotlib, J.2    Pollyea, D.A.3
  • 17
    • 84880976662 scopus 로고    scopus 로고
    • Somatic SETBP1 mutations in myeloid malignancies
    • Makishima H, Yoshida K, Nguyen N, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013; 45:942-946.
    • (2013) Nat Genet , vol.45 , pp. 942-946
    • Makishima, H.1    Yoshida, K.2    Nguyen, N.3
  • 18
    • 84871988651 scopus 로고    scopus 로고
    • Recurrent SETBP1 mutations in atypical chronic myeloid leukemia
    • Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45:18-24.
    • (2013) Nat Genet , vol.45 , pp. 18-24
    • Piazza, R.1    Valletta, S.2    Winkelmann, N.3
  • 19
    • 84986253588 scopus 로고    scopus 로고
    • Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
    • Patnaik MM, Lasho TL, Vijayvargiya P, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J 2016; 6:e385
    • (2016) Blood Cancer J , vol.6 , pp. e385
    • Patnaik, M.M.1    Lasho, T.L.2    Vijayvargiya, P.3
  • 20
    • 84885644431 scopus 로고    scopus 로고
    • SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: Independent prognostic impact in CMML
    • Laborde RR, Patnaik MM, Lasho TL, et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: Independent prognostic impact in CMML. Leukemia 2013; 27:2100-2102.
    • (2013) Leukemia , vol.27 , pp. 2100-2102
    • Laborde, R.R.1    Patnaik, M.M.2    Lasho, T.L.3
  • 21
    • 79960227474 scopus 로고    scopus 로고
    • Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms
    • Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011; 25:1200-1202.
    • (2011) Leukemia , vol.25 , pp. 1200-1202
    • Abdel-Wahab, O.1    Pardanani, A.2    Patel, J.3
  • 22
    • 84865152223 scopus 로고    scopus 로고
    • ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression
    • Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012; 22:180-193.
    • (2012) Cancer Cell , vol.22 , pp. 180-193
    • Abdel-Wahab, O.1    Adli, M.2    LaFave, L.M.3
  • 23
    • 84934945331 scopus 로고    scopus 로고
    • Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex
    • Balasubramani A, Larjo A, Bassein JA, et al. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex. Nat Commun 2015; 6:7307
    • (2015) Nat Commun , vol.6 , pp. 7307
    • Balasubramani, A.1    Larjo, A.2    Bassein, J.A.3
  • 24
    • 84922336738 scopus 로고    scopus 로고
    • Prognostic score including gene mutations in chronic myelomonocytic leukemia
    • Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31:2428-2436.
    • (2013) J Clin Oncol , vol.31 , pp. 2428-2436
    • Itzykson, R.1    Kosmider, O.2    Renneville, A.3
  • 25
    • 84888219405 scopus 로고    scopus 로고
    • Clinical and biological implications of driver mutations in myelodysplastic syndromes
    • quiz 3699.
    • Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013;122:3616-3627. quiz 3699.
    • (2013) Blood , vol.122 , pp. 3616-3627
    • Papaemmanuil, E.1    Gerstung, M.2    Malcovati, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.